Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme

Showing 201 to 250 of 2054

TitleReference numberPublishedLast updated
Difelikefalin for treating pruritus in people having haemodialysisTA890
Diabetes (type 1 and type 2) in children and young people: diagnosis and managementNG18
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapyTA886
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancerTA887
Point-of-care tests for urinary tract infections to improve antimicrobial prescribing: early value assessmentHTE7
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatmentsTA881
Voclosporin with mycophenolate mofetil for treating lupus nephritisTA882
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphomaTA883
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)TA884
Metastatic malignant disease of unknown primary origin in adults: diagnosis and managementCG104
Tezepelumab for treating severe asthmaTA880
Lumasiran for treating primary hyperoxaluria type 1HST25
Onasemnogene abeparvovec for treating spinal muscular atrophyHST15
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiencyHST26
Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophyHST24
Daytime intraoral neuromuscular electrical tongue stimulation using a removable device for obstructive sleep apnoeaIPG760
Endoscopic ultrasound-guided biliary drainage for biliary obstructionIPG761
Hypertension in pregnancy: diagnosis and managementNG133
AposHealth for knee osteoarthritisMTG76
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)TA879
Radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastasesIPG759
Percutaneous thoracic duct embolisation for persistent chyle leakIPG755
Focal therapy using high-intensity focused ultrasound for localised prostate cancerIPG756
Maximal cytoreductive surgery for advanced ovarian cancerIPG757
Radiofrequency ablation for palliation of painful spinal metastasesIPG758
UrgoStart for treating diabetic foot ulcers and leg ulcersMTG42
Acute kidney injuryQS76
Finerenone for treating chronic kidney disease in type 2 diabetesTA877
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancerTA876
CaRi-Heart for predicting cardiac risk in suspected coronary artery disease: early value assessmentHTE4
Type 1 diabetes in adultsQS208
Type 2 diabetes in adultsQS209
Asfotase alfa for treating paediatric-onset hypophosphatasiaHST23
Endoluminal gastroplication for gastro-oesophageal reflux diseaseIPG753
Percutaneous transluminal renal sympathetic denervation for resistant hypertensionIPG754
Eptinezumab for preventing migraineTA871
Cannabidiol for treating seizures caused by tuberous sclerosis complexTA873
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphomaTA874
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapiesTA872
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin geneHST22
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myelomaTA870
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)TA867
Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal)TA869
Urinary tract infections in adultsQS90
Vutrisiran for treating hereditary transthyretin-related amyloidosisTA868
Antenatal careQS22
Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and managementNG231
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinomaTA865
Regorafenib for previously treated metastatic colorectal cancerTA866
Transvenous obliteration for gastric varicesIPG751

Results per page

  1. 10
  2. 25
  3. 50
  4. All